Buprenorphine/naloxone (Suboxone®) as substitution treatment for opioid dependence
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000441
English
Authors' recommendations:
Buprenorphine/naloxone (Suboxone®) is recommended for restricted use within NHS Wales as substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. In accordance with NICE guidance such treatment should
be considered in patients who are unsuitable for maintenance treatment with methadone.
Details
Project Status:
Completed
Year Published:
2008
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=100591&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Opioid-Related Disorders
- Opiate Substitution Treatment
- Buprenorphine
- Naloxone
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.